Based on customer feedback, we have begun converting some of our popular BD OptiBuild™ On-Demand Reagents to our standard, off-the-shelf reagents. While converted products will have new catalog numbers, they will be available at improved pricing and in familiar 50-μg unit sizes.
What you can expect:
- Off-the-shelf availability with improved pricing
- Access to single lot material
- Representative data provided on the Technical Data Sheet (TDS)
A transition period of at least 6 months for comparison testing and study completion prior to the obsolescence of BD OptiBuild™ Reagent catalog numbers
View product list highlighting the legacy BD OptiBuild™ Reagents along with the new off-the-shelf catalog numbers below.
Performance Data
Comparison of legacy BD OptiBuild™ On-Demand Reagents and converted equivalent
off-the-shelf BD Horizon™ Reagents demonstrating similar performance.
A. Flow cytometric comparison of NK-1.1 staining on mouse splenocytes using BD Horizon™ BV786 (blue histogram) or BD Optibuild™ BV786 Reagents (orange histogram) Mouse Anti-Mouse NK-1.1 antibody.
Splenic leucocytes from a C57BL/6 mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™). The cells were then stained with BV786 Mouse Anti-Mouse NK-1.1 antibodies at 0.5 ug/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The fluorescence histograms showing NK-1.1 expression were derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) splenic leucocytes.
B. Two-color flow cytometric comparison of NK-1.1 staining on mouse splenocytes using BD Horizon™ BV786 (left) or BD OptiBuild™ BV786 (right) Mouse Anti-Mouse NK-1.1 Reagents
Splenic leucocytes from a C57BL/6 mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™). The cells were then stained with PE Hamster Anti-Mouse CD3e antibody and BV786 Mouse Anti-Mouse NK-1.1 antibodies at 0.5 ug/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. Two-color flow cytometric dot plots show the correlated expression patterns of NK1.1 versus CD3e for gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) splenic leucocytes.
A. Flow cytometric comparison of CD8 staining on human peripheral blood lymphocytes using BD Horizon™ BV421 (blue histogram) or BD OptiBuild™ BV421 (orange histogram) Mouse Anti-Human CD8 Reagents.
Whole blood was stained with BV421 Mouse Anti-Human CD8 antibodies at 0.25 µg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution. The fluorescence histogram showing CD8 expression was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes.
B. Flow cytometric comparison of CD8 staining using BD Horizon™ BV421 (left) or BD OptiBuild™ BV421 (right) Mouse Anti-Human CD8 antibody (clone SK1).
Whole blood was stained with BV421 CD8 antibodies at 0.25 µg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution. The bivariate pseudocolor density plots showing the correlated expression of CD8 versus side light-scatter (SSC-A) signals were derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations.
A. Flow cytometric comparison of CD19 staining on human peripheral blood lymphocytes using BD Horizon™ BV480 (blue histogram) or BD OptiBuild™ BV480 (orange histogram) Mouse Anti-Human CD19 Reagents.
Whole blood was stained with BV480 Mouse Anti-Human CD19 antibodies at 0.25 µg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution. The fluorescence histograms showing CD19 expression were derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes.
B. Flow cytometric comparison of CD19 staining using BD Horizon™ BV480 (left) or BD Optibuild™ BV480 (right) Mouse Anti-Human CD19 Reagents.
Whole blood was stained with BV480 Mouse Anti-Human CD19 antibodies at 0.25 µg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution. The bivariate pseudocolor density plots showing the correlated expression of CD19 versus side light-scatter (SSC-A) signals were derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations.
A. Flow cytometric comparison of ICOS (CD278) staining on stimulated human peripheral blood lymphocytes using BD Horizon™ BUV563 (blue histogram) or BD OptiBuild™ BUV563 (orange histogram) Mouse Anti-Human ICOS (CD278) Reagents.
Phytohemagglutinin (PHA)-stimulated (3 days) peripheral blood mononuclear cells were stained with Mouse Anti-Human ICOS (CD278) antibodies at 0.25 ug/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The fluorescence histogram showing ICOS (CD278) expression was derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) lymphocytes.
B. Flow cytometric comparison of ICOS (CD278) staining on stimulated human peripheral blood lymphocytes using BD Horizon™ BUV563 (left) or BD Optibuild™ BUV563 (right) Mouse Anti-Human ICOS (CD278) antibody.
Phytohemagglutinin (PHA)-stimulated (3 days) peripheral blood mononuclear cells were stained with Mouse Anti-Human ICOS (CD278) antibodies at 0.25 ug/T. BD Via-Probe™ Cell Viability 7-AAD Solution was added to cells right before analysis. The bivariate pseudocolor density plots showing the correlated expression of ICOS (CD278) versus side light-scatter (SSC-A) signals were derived from gated events with the forward and side light-scatter characteristics of viable (7-AAD-negative) lymphocytes.
A. Flow cytometric comparison of CD314 (NKG2D) staining on human peripheral blood lymphocytes using BD Horizon™ BV421 (blue histogram) or BD OptiBuild™ BV421 (orange histogram) Mouse Anti-Human CD314 (NKG2D) Reagents.
Whole blood was stained with Mouse Anti-Human CD314 (NKG2D) at 0.5 µg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution. The fluorescence histogram showing CD314 (NKG2D) expression was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes.
B. Two-color flow cytometric comparison of CD314 (NKG2D) staining on human peripheral blood lymphocytes using BD Horizon™ BV421 (A) or BD OptiBuild™ BV421 (B) Mouse Anti-Human CD314 (NKG2D) Reagents.
Whole blood was stained with PE Anti-Human CD56 and BV421 Mouse Anti-Human CD314 (NKG2D) antibodies at 0.5 µg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution. A bivariate pseudocolor density plot showing the correlated expression of CD314 (NKG2D) versus CD56 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes.
Product Transition Chart
| Legacy BD & OptiBuild™ Reagent Catalog Number | Species | Description | Clone | Isotype | Format | New BD Horizon™ Reagent Catalog Number |
|---|---|---|---|---|---|---|
| 740660 | Mouse | Ms CD62L BV711 MEL-14 50 µg | MEL-14 | Rat IgG2a, κ | BV711 | 568286 |
| 740853 | Mouse | Ms NK-1.1 BV786 PK136 50 µg | PK136 | Mouse IgG2a | BV786 | 568224 |
| 742484 | Mouse | Ms TCR b Chain BV786 H57-597 50 µg | H57-597 | Ham IgG2, λ1 | BV786 | 568222 |
| 749027 | Mouse | Ms CD19 BUV805 1D3 50 µg | 1D3 | Mouse IgG1, κ | BUV805 | 568287 |
| 740093 | Human | Hu CD8 BV421 SK1 50 µg | SK1 | Mouse IgG1, κ | BV421 | 568217 |
| 740722 | Mouse | Hu CD123 BV711 7G3 50 µg | 7G3 | Mouse IgG2a, κ | BV711 | 568228 |
| 740771 | Human | Hu CD11b BV711 ICRF44 50 µg | ICRF44 | Mouse IgG1, κ | BV711 | 568229 |
| 740801 | Human | Hu CD80 BV711 L307.4 50 µg | L307.4 | Mouse IgG1, κ | BV711 | 568227 |
| 740966 | Human | Hu CD11c BV786 B-ly6 50 µg | B-ly6 | Mouse IgG1, κ | BV786 | 568220 |
| 740971 | Human | Hu CD24 BV786 ML5 50 µg | ML5 | Mouse IgG2a | BV786 | 568225 |
| 741003 | Human | Hu CD163 BV786 GHI/61 50 µg | GHI/61 | Mouse IgG1, κ | BV786 | 568221 |
| 741006 | Human | Hu CD141 BV786 1A4 50 µg | 1A4 | Mouse IgG1, κ | BV786 | 568218 |
| 741013 | Human | Hu CD15 BV786 W6D3 50 µg | W6D3 | Mouse IgG1, κ | BV786 | 568288 |
| 741421 | Human | Hu ICOS (CD278) BUV563 DX29 50 µg | DX29 | Mouse IgG1, κ | BUV563A | 568215 |
| 741826 | Human | Hu CD11b BUV737 ICRF44 50 µg | ICRF44 | Mouse IgG1, κ | BUV737 | 568332 |
| 741827 | Human | Hu CD11c BV737 B-ly6 50 µg | B-ly6 | Mouse IgG1, κ | BUV737 | 568328 |
| 741861 | Human | Hu CD137 BUV737 4B4-1 50 µg | 4B4-1 | Mouse IgG1, κ | BUV737 | 568348 |
| 741872 | Human | Hu CD3 BUV737 SP34-2 50 µg | SP34-2 | Mouse IgG1, λ1 | BUV737 | 568353 |
| 742007 | Human | Hu CD19 BUV805 HIB19 50 µg | HIB19 | Mouse IgG1, κ | BUV805 | 568331 |
| 742020 | Human | Hu CD45RA BUV805 HI100 50 µg | HI100 | Mouse IgG2b, κ | BUV805 | 568330 |
| 742053 | Human | Hu CD3 BUV805 SP34-2 50 µg | SP34-2 | Mouse IgG1, λ1 | BUV805 | 568354 |
| 742229 | Human | Hu CD8 BB700 HIT8a 50 µg | HIT8a | Mouse IgG1, κ | BB700 | 568284 |
| 742731 | Human | Hu CD27 BV421 L128 50 µg | L128 | Mouse IgG1, κ | BV421 | 568226 |
| 743172 | Human | Hu CD337 (NKp30) BV786 P30-15 50 µg | P30-15 | Mouse IgG1, κ | BV786 | 568223 |
| 743283 | Human | Hu CD134 BV421 ACT35 50 µg | ACT35 | Mouse IgG1, κ | BV421 | 568213 |
| 743558 | Human | Hu CD314 (NKG2D) BV421 1D11 50 µg | 1D11 | Mouse IgG1, κ | BV421 | 568106 |
| 743654 | Human | Hu CD103 BV786 Ber-ACT8 50 µg | Ber-ACT8 | Mouse IgG1, κ | BV786 | 568274 |
| 746313 | Human | Hu CD3 BV480 HIT3A 50 µg | HIT3a | Mouse IgG2a, κ | BV480 | 568216 |
| 746457 | Human | Hu CD19 BV480 HIB19 50 µg | HIB19 | Mouse IgG1, κ | BV480 | 568214 |
| 747522 | Human | Hu CD69 BV750 FN50 50ug | FN50 | Mouse IgG1, κ | BV750 | 568285 |
| 748338 | Human | Hu HLA-DR BUV805 G46-6 50 µg | G46-6 | Mouse IgG2a, κ | BUV805 | 568335 |
| 748339 | Human | Hu HLA-DR BUV737 G46-6 50 µg | G46-6 | Mouse IgG2a, κ | BUV737 | 568351 |
| 748502 | Human | Hu CD103 BUV737 Ber-ACT8 50 µg | Ber-ACT8 | Mouse IgG1, κ | BUV737 | 568350 |
| 748851 | Human | Hu CD16 BUV563 3G8 50 µg | 3G8 | Mouse IgG1, κ | BUV563 | 568289 |
| 749173 | Human | Hu CD19 BUV805 SJ25C1 50 µg | SJ25C1 | Mouse IgG1, κ | BUV805 | 568290 |
| 749366 | Human | Hu CD8 BUV805 RPA-T8 50 µg | RPA-T8 | Mouse IgG2a, κ | BUV805 | 568334 |
BV: BD Horizon Brilliant Violet™ Reagents
BUV: BD Horizon Brilliant™ Ultraviolet Reagents
The product list will be updated with future releases
For Research Use Only. Not for use in therapeutic or diagnostic procedures.
